Hematologic Malignancies
Specialty Channel

Featured Article
Jonathan Kaufman, MD, discusses his study about targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory MM.
Tazemetostat yielded durable responses and was generally well tolerated in a recent study of heavily pretreated patients with relapse or refractory follicular lymphoma (FL; Lancet Oncol. 2020 Oct 6.…
Treatment with _____ of blinatumomab led to an improvement in EFS when compared with consolidation therapy before allogenic hematopoietic stem cell transplant in young patients with relapsed or…
Blinatumomab leads to an improvement in event-free survival (EFS) when compared to consolidation chemotherapy in young patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL…
True or False: Does inotuzumab ozogamicin yield anti-leukemia activity in young patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)?
Prognostic biomarker testing rates for patients with CLL and SLL is low, indicating the need for more comprehensible treatment options, according to data presented at the virtual ONS Congress.
The FDA has approved loncastuximab tesirine-lpyl for patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy.
True or False: Oral azacitidine significantly improved RBC transfusion independence rates and included durable bilineage improvements in patients with lower-risk MDS and high-risk disease features.
Oral azacitidine significantly improved RBC-TI rates and induced durable bilineage improvements in patients with lower-risk MDS and high-risk disease features, according to a phase 3 trial.

News

Tazemetostat yielded durable responses and was generally well tolerated in a recent study of heavily pretreated patients with relapse or refractory follicular lymphoma (FL; Lancet Oncol. 2020 Oct 6.…
Blinatumomab leads to an improvement in event-free survival (EFS) when compared to consolidation chemotherapy in young patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL…
Prognostic biomarker testing rates for patients with CLL and SLL is low, indicating the need for more comprehensible treatment options, according to data presented at the virtual ONS Congress.
The FDA has approved loncastuximab tesirine-lpyl for patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy.

Interactive Features

Among patients with FL, approximately what percentage are reported as having activating mutations of EZH2?
Treatment with _____ of blinatumomab led to an improvement in EFS when compared with consolidation therapy before allogenic hematopoietic stem cell transplant in young patients with relapsed or…
True or False: Does inotuzumab ozogamicin yield anti-leukemia activity in young patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL)?
True or False: Oral azacitidine significantly improved RBC transfusion independence rates and included durable bilineage improvements in patients with lower-risk MDS and high-risk disease features.
Stay in the know.
OncNet Newsletter